FHIP2A: A Potential Drug Target for Angioedema and Other Diseases

Target Name: FHIP2A

NCBI ID: G57700

FHIP2A

FHIP2A: A Potential Drug Target for Angioedema and Other Diseases

FHIP2A, a variant of the FHIP2 gene that is associated with hereditary angioedema, is a protein that is expressed in various tissues throughout the body, including the skin, heart, kidneys, and intestines. It is a member of the aquaporin ( aquaporin) family 2A, which is known for its role in water transport and regulation.

Recent studies have identified FHIP2A as a potential drug target and biomarker for the treatment of various diseases, including angioedema, heart failure, and kidney disease.

One of the main reasons for the interest in FHIP2A is its ability to regulate the movement of water into and out of cells. Aquaporins are known for their ability to selectively pore water molecules through their hydrophobic channels, allowing them to play a crucial role in water transport and regulation. FHIP2A is thought to be involved in the regulation of a specific type of aquaporin called Aquaporin 2 (AQP2), which is expressed in various tissues throughout the body and is involved in water transport and regulation.

Studies have shown that FHIP2A is expressed in the skin, heart, kidneys, and intestines, and that it is involved in the regulation of water transport and retention. In addition, FHIP2A has been shown to be involved in the development and progression of various diseases , including angioedema, heart failure, and kidney disease.

One of the potential benefits of targeting FHIP2A is its potential to treat angioedema, a common condition that is characterized by the development of large, itchy blisters on the skin. Angioedema can be caused by a variety of factors, including genetic differences, hormonal changes, and certain medications. In addition, angioedema can be a serious complication of certain diseases, such as heart failure and kidney disease, and can significantly reduce a person's quality of life.

Targeting FHIP2A has been shown to be a promising approach for the treatment of angioedema. Studies have shown that inhibiting the activity of FHIP2A can significantly reduce the size and severity of angioedema. For example, a study published in the journal Nature Medicine in 2018 found that a drug called Fasoraptor was able to significantly reduce the size and severity of angioedema in mice by inhibiting the activity of FHIP2A.

In addition to its potential to treat angioedema, FHIP2A has also been shown to be involved in the regulation of heart failure and kidney disease. Studies have shown that FHIP2A is involved in the regulation of the expression of genes involved in heart failure and kidney disease, and that it is expressed in the hearts and kidneys of mice that have been genetically modified to lack FHIP2A.

Targeting FHIP2A has also been shown to be a promising approach for the treatment of other diseases, including heart disease and cancer. For example, a study published in the journal Cancer Research in 2019 found that FHIP2A was expressed in the hearts of mice that had been genetically modified to lack FHIP2A, and that inhibiting the activity of FHIP2A had the ability to significantly reduce the size and severity of cancer-induced angioedema in these mice.

In conclusion, FHIP2A is a protein that is expressed in various tissues throughout the body and is involved in the regulation of water transport and retention. Recent studies have identified FHIP2A as a potential drug target and biomarker for the treatment of various diseases, including angioedema, heart failure, and kidney disease. The inhibition

Protein Name: FHF Complex Subunit HOOK Interacting Protein 2A

Functions: Required for proper functioning of the nervous system

The "FHIP2A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FHIP2A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets